Journal de pharmacocinétique et thérapeutique expérimentale

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Population Pharmacokinetics and Optimization of the Dosing Regimen of Digoxin in Adult Patients

Toshiaki Komatsu, Mami Morita, Futaba Miyaji, Takayuki Inomata, Junya Ako and Koichiro Atsuda

Background Lanoxin is wide prescribed for the treatment of symptom cardiopathy and cardiac arrhythmia. healing drug observation of Lanoxin is suggested due to its slender healing vary. previous research have reportable many equations and nomograms to alternate physicians to work out the desirable dose of Lanoxin for character sufferers. moreover, populace pharmacokinetic information imply that clearance of Lanoxin is encouraged by demographic variables like age, overall weight, and blood serum creatinine stages. however, population materia medica has now not been studied up to now to judge the impact of concomitant administration of medication like amiodarone, verapamil, and tolvaptan on relative Lanoxin clearance. currently, the therapeutic range for Lanoxin in patients with cardiopathy with a traditional sinus rhythm has been revised to a low and slender vary (0.5-zero.eight ng/mL) supported the findings from the digitalis investigation cluster trial. for the duration of this look at, we generally tend to aimed to investigate the populace materia medica of Lanoxin in the presence of concomitant management of various medication. what's extra, we generally tend to decided preliminary dosing regimens to attain concentrations (0.five-zero.8 ng/mL) in step with our population pharmacokinetic information.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.